US-based biopharmaceutical firm Cubist Pharmaceuticals has completed the acquisition of Trius Therapeutics, which is focused on the development of antibiotics, for about $704m. The acquisition of Trius brings to Cubist a late-stage ...
Cubist Pharmaceuticals has entered into two separate agreements to acquire Optimer Pharmaceuticals and Trius Therapeutics, as part of the company's Building Blocks of Growth strategy to strengthen its presence in acute care and hospital ...